TDP-43, a protein normally busy managing RNA inside the cell nucleus, is the central culprit in roughly 97% of ALS cases and about half of frontotemporal dementia cases. When TDP-43 evacuates the nucleus and clumps in the cytoplasm, it sets off a cascade of damage: the genes it once regulated go haywire, the protein aggregates poison nearby cells, and the pathology spreads through the nervous system in a predictable anatomical pattern. Understanding how this spread happens and why motor neurons are so vulnerable to it has become the defining question in ALS research over the past decade.
What TDP-43 Does in a Healthy Cell
TDP-43 (short for TAR DNA-binding protein 43) is an RNA- and DNA-binding protein that performs essential housekeeping in virtually every cell in your body. Its main jobs include splicing RNA transcripts, regulating which genes get turned on, and stabilizing RNA molecules so they survive long enough to be translated into proteins.1PubMed Central. Structural insights and milestones in TDP-43 research: A comprehensive review of its pathological and therapeutic advances In neurons, these functions are especially critical because nerve cells are long-lived, metabolically demanding, and rely on precise protein production at faraway locations along their axons. TDP-43 normally resides in the nucleus, shuttling back and forth to the cytoplasm as needed. That balance between nuclear and cytoplasmic localization turns out to be the linchpin of the disease.
What Goes Wrong When TDP-43 Leaves the Nucleus
In ALS motor neurons, TDP-43 drains out of the nucleus and accumulates in the cytoplasm, where it forms insoluble clumps. This creates a two-pronged problem. First, the nucleus loses its supply of TDP-43 and can no longer properly manage RNA splicing. Second, the cytoplasmic aggregates are directly toxic to the cell. Researchers sometimes describe this as a simultaneous loss-of-function and gain-of-toxicity, and both arms appear to matter.
The loss-of-function side is now better understood thanks to work on two genes in particular: STMN2 and UNC13A. When TDP-43 is depleted from the nucleus, aberrant “cryptic” segments of RNA that are normally silenced get spliced into the messenger RNA for stathmin-2 (encoded by STMN2), a protein required for axonal regeneration and maintenance.2PubMed Central. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies The result is a truncated, nonfunctional version of stathmin-2. UNC13A, a gene involved in synaptic transmission, suffers a similar fate, disrupting the neuron’s ability to communicate at synapses and extend its processes.3PubMed Central. U7 small nuclear RNA splice-switching therapeutics for STMN2 and UNC13A in Amyotrophic Lateral Sclerosis So even if you could somehow neutralize the toxic clumps, the neuron would still be in trouble because its nuclear RNA processing has broken down.
How TDP-43 Aggregates Form and Why They Persist
Once TDP-43 lands in the cytoplasm, it undergoes a series of chemical modifications that make it stickier and harder for the cell to dispose of. One key event is cleavage by enzymes called caspases, which chop the full-length protein into smaller fragments. A roughly 25-kilodalton C-terminal fragment is particularly prone to forming toxic, insoluble inclusions that become decorated with ubiquitin and phosphate groups.4PubMed Central. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity These inclusions are the signature pathological finding when neuropathologists examine ALS brain and spinal cord tissue.
Phosphorylation of TDP-43 at specific sites in its C-terminal region has long been assumed to drive aggregation, and pathologists use antibodies against phosphorylated TDP-43 (pTDP-43) to map disease progression. But the actual role of phosphorylation turns out to be more complicated than the textbook version. Work in cell models has shown that extensive phosphorylation by the enzyme casein kinase 1δ can actually make TDP-43 condensates more liquid-like and dynamic, suppressing rather than promoting aggregation.5PubMed Central. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation This counterintuitive finding suggests that phosphorylation might initially be a protective response that fails over time, rather than a straightforward driver of clumping. It also complicates therapeutic strategies that aim to block phosphorylation, since doing so could paradoxically accelerate solid aggregate formation.
Phase Separation and the Shift From Liquid to Solid
TDP-43 belongs to a class of proteins that can form liquid-like droplets inside cells through a process called phase separation, somewhat like oil droplets forming in water. Under normal conditions, these droplets are dynamic: molecules flow in and out, and the droplets can fuse and dissolve as the cell’s needs change. This behavior is tied to stress granules, temporary structures that neurons assemble during cellular stress to park RNA molecules until conditions improve.
The problem in ALS is that these liquid droplets can undergo a transition to a more rigid, solid-like state. Mutations in TDP-43’s low-complexity domain, or disruptions to its interactions with certain molecular partners, push the protein toward forming irregular, solid structures that no longer behave like normal liquid droplets.6Molecular Cell. Tankyrase-1/2 Inhibition Mitigates TDP-43 Driven Neurodegeneration by Inhibiting Phase Separation and Stress Granule Formation Once this liquid-to-solid transition occurs, the aggregates become self-reinforcing: they seed further aggregation, resist clearance, and trap other essential proteins. This is one reason why ALS pathology, once established, tends to be progressive and difficult to reverse.
Nuclear Pore Damage Creates a Vicious Cycle
TDP-43 aggregates do not just sit passively in the cytoplasm. They actively interfere with the nuclear pore complexes, the gateways that control traffic between the nucleus and cytoplasm. Research using proximity-labeling techniques found that insoluble TDP-43 aggregates are enriched for components of the nuclear pore and nucleocytoplasmic transport machinery. The aggregates sequester and mislocalize nucleoporins and transport factors, impairing both protein import into the nucleus and RNA export out of it.7PubMed. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD This creates a vicious cycle: the more TDP-43 accumulates in the cytoplasm, the more it damages the machinery that would normally shuttle proteins back into the nucleus, which in turn traps even more TDP-43 outside the nucleus. Nuclear pore pathology has been confirmed in brain tissue from people with sporadic ALS as well as those with genetic mutations in TARDBP and C9orf72, suggesting it is a common feature of the disease rather than an artifact of any single mutation.
The Four-Stage Spreading Pattern
One of the most striking features of TDP-43 pathology in ALS is that it does not hit the entire nervous system at once. Postmortem studies have revealed a remarkably consistent four-stage progression. In stage 1, phosphorylated TDP-43 inclusions appear in the motor cortex, certain brainstem motor nuclei, and spinal cord motor neurons. By stage 2, pathology has spread to the prefrontal cortex, brainstem reticular formation, and several precerebellar nuclei. Stage 3 brings involvement of additional prefrontal and postcentral cortical areas and the striatum. In stage 4, pathology reaches the temporal lobe, including the hippocampus.8PubMed Central. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis At every stage, oligodendroglial cells (the support cells that insulate nerve fibers) also show TDP-43 aggregates. Cases carrying C9orf72 repeat expansions follow the same sequence but with a heavier burden at each stage, suggesting a more aggressive dissemination.
This orderly march through connected brain regions raises an obvious question: is the pathology spreading along the brain’s wiring? Computational modeling supports exactly that idea. Simulations of disease propagation through the brain’s white-matter connections, starting from the motor regions affected in stage 1, reproduce the sequential pattern seen in neuropathology staging.9PubMed. Simulating disease propagation across white matter connectome reveals anatomical substrate for neuropathology staging in amyotrophic lateral sclerosis The spread is constrained by the physical connections between brain regions, much like a fire that travels along corridors rather than jumping randomly between rooms.
How TDP-43 Pathology Moves Between Cells
If TDP-43 pathology spreads along axonal connections, there must be a mechanism by which misfolded protein transfers from one cell to the next. Extracellular vesicles, tiny membrane-bound parcels that cells release into their surroundings, are a leading candidate. These vesicles can carry misfolded TDP-43 and associated RNA cargo from affected cells to healthy neighbors, essentially serving as delivery vehicles for pathological protein.10SpringerLink. Extracellular vesicles and amyotrophic lateral sclerosis: from misfolded protein vehicles to promising clinical biomarkers In cell culture and animal models, this vesicle-mediated transmission can seed new aggregation in recipient cells, providing a plausible mechanism for the stage-by-stage spread observed in human brains.
This mode of spreading also helps explain why ALS symptoms typically begin in one body region and fan outward. If a patient first develops weakness in one hand, the pathology may be propagating from the corresponding motor cortex and spinal cord segment to adjacent segments, following the physical layout of the motor neuron network. It is not that every motor neuron independently develops its own TDP-43 problem at the same time; rather, the disease appears to be transmitted, region by region, through interconnected circuits.
Mitochondrial Damage and Failing Axonal Transport
Motor neurons are among the largest cells in the body, with axons that can stretch a meter or more from the spinal cord to the muscles they control. Keeping those axons supplied with energy, proteins, and organelles requires a sophisticated transport system powered by molecular motor proteins. TDP-43 pathology sabotages this system at multiple levels.
At the energy level, abnormal TDP-43 expression damages mitochondria directly. In cellular and animal models, elevated TDP-43 reduces mitochondrial membrane potential, suppresses the activity of complex I in the electron transport chain, and cuts ATP production. At the same time, it ramps up production of reactive oxygen species, bathing the cell in oxidative stress.11PLOS Genetics. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response For a motor neuron that already runs a razor-thin energy budget to maintain its enormous axon, this mitochondrial dysfunction can be catastrophic.
The transport machinery itself also breaks down. Studies in motor neurons derived from stem cells carrying ALS-linked TDP-43 mutations show downregulation of several key motor proteins, including dynein, dynactin-1, and members of the kinesin family (KIF5A, KIF5B) that carry cargo along microtubule tracks.12Brain Communications. Dynactin-1 mediates rescue of impaired axonal transport due to reduced mitochondrial bioenergetics in amyotrophic lateral sclerosis motor neurons When these motors are depleted, mitochondria, synaptic vesicles, and other cargo pile up or fail to reach the nerve terminals, starving the distal axon. The combination of less energy being produced and less of it being delivered to where it is needed helps explain why motor neuron terminals die back before the cell body does, a pattern called “dying back” that clinicians observe in ALS.
Glial Cells Turn Against Motor Neurons
Motor neurons do not die in isolation. The glial cells that surround and support them actively contribute to their destruction once TDP-43 pathology takes hold. Astrocytes, the most abundant glial cells in the central nervous system, become reactive and harmful. In rats engineered to express mutant TDP-43 specifically in astrocytes, the animals developed progressive motor neuron loss even though the motor neurons themselves did not carry the mutation. The toxic astrocytes showed depletion of glutamate transporters GLT-1 and GLAST, which normally clear excess glutamate from synapses, and they began producing the neurotoxic factor Lcn2.13PubMed Central. Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in rats The depletion of glutamate transporters means the neurotransmitter lingers at synapses, overstimulating motor neurons in a process known as excitotoxicity.
Microglia, the brain’s resident immune cells, pile on as well. When TDP-43 is released from dying neurons into the extracellular space, microglia recognize it through their CD14 surface receptor and launch an inflammatory response involving the NF-κB signaling pathway and the NLRP3 inflammasome. This inflammatory cascade is directly toxic to motor neurons in culture; when microglia were removed from the system, TDP-43 alone was not enough to kill the neurons.14Experimental Neurology. TDP-43 activates microglia through NF-kappa B and NLRP3 inflammasome The implication is striking: a significant portion of motor neuron death in ALS may be driven not by what happens inside the motor neuron itself but by the inflammatory environment created by surrounding glial cells responding to TDP-43. This “non-cell-autonomous” toxicity is one reason why therapies targeting motor neurons alone have had limited success.
Why the Cell’s Cleanup Systems Fail
Cells have two main systems for disposing of damaged or aggregated proteins: the ubiquitin-proteasome system, which tags and shreds individual misfolded proteins, and autophagy, which wraps larger clumps in membranes and delivers them to lysosomes for digestion. Both systems play a role in clearing TDP-43, with the proteasome handling soluble forms and autophagy tackling the larger aggregates.15PubMed Central. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species In ALS, both pathways appear to be overwhelmed.
Part of the problem is aging itself. The efficiency of proteasomal degradation and autophagy declines with age in all tissues, and the motor neuron system starts losing its buffer capacity. But there may also be a “second hit” at work: ALS-linked mutations in genes connected to protein clearance pathways, or the sheer burden of aggregated TDP-43, can push an already-weakened system past its breaking point.16PubMed. TDP-43 pathology: From noxious assembly to therapeutic removal The heat-shock response and chaperone-mediated autophagy, two additional cleanup mechanisms, also decline in the disease. The net effect is that once TDP-43 aggregates begin forming, the cell’s ability to clear them diminishes in lockstep, creating another self-reinforcing loop.
Genetic Mutations and the Sensitivity of Subcellular Balance
Only a small fraction of ALS cases involve mutations in the TARDBP gene that encodes TDP-43, but studying those mutations has been revealing. TARDBP mutations confer a baseline increase in cytoplasmic TDP-43, suggesting that even modest shifts in where the protein sits within the cell can initiate early pathology.17Molecular Neurodegeneration. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis The downstream consequences include altered splicing regulation, heightened sensitivity to cellular stress, increased DNA damage, and broad changes across the transcriptome. The fact that such small changes in localization can cascade into widespread cellular dysfunction underscores how finely tuned the TDP-43 system is in healthy neurons.
TDP-43 pathology also shows up in frontotemporal dementia, where the same abnormal C-terminal fragments are ubiquitinated, hyperphosphorylated, and deposited in neurons and glia.18PubMed Central. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia This overlap has led researchers to classify ALS and the most common pathological subtype of frontotemporal dementia as a single disease spectrum, sometimes called TDP-43 proteinopathies, rather than two unrelated conditions. Whether a patient develops primarily motor symptoms (ALS), primarily cognitive and behavioral symptoms (FTD), or a mixture depends on which brain regions bear the heaviest burden of TDP-43 pathology.
Modeling TDP-43 Disease in the Lab
Much of what we know about TDP-43 mechanisms comes from cell and animal models, and a recurring challenge is making sure those models faithfully replicate what happens in human neurons. Motor neurons grown from patient-derived stem cells have become a powerful tool. In these cells, researchers can observe the same cryptic splicing events seen in postmortem ALS tissue: STMN2, UNC13A, and dozens of other TDP-43-dependent genes are downregulated in motor neurons carrying TARDBP or PFN1 mutations, closely matching the gene-expression changes found in human postmortem lower motor neurons.19Cell Reports. Cell-type-specific postmortem ALS gene expression changes are recapitulated in human iPSC-derived motor neurons Interestingly, motor neurons carrying a SOD1 mutation, which causes ALS through a TDP-43-independent mechanism, did not show the same pattern, reinforcing that TDP-43-mediated and SOD1-mediated ALS are mechanistically distinct despite sharing a clinical diagnosis.
Therapeutic Approaches Targeting TDP-43
The growing understanding of TDP-43 pathology has opened several therapeutic angles. One of the most advanced is the use of antisense oligonucleotides (ASOs), short synthetic DNA-like molecules that can selectively reduce the production of a target protein. In mouse models expressing human TDP-43, a single injection of an ASO targeting TDP-43 messenger RNA produced a marked reduction in TDP-43 protein levels across the brain and spinal cord. More strikingly, the treatment improved behavioral symptoms in the mice and, months later, shifted TDP-43 back to a predominantly nuclear localization with far fewer cytoplasmic aggregates compared to untreated animals.20PubMed Central. Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice The fact that a transient reduction in TDP-43 could yield sustained benefits months later suggests there may be a therapeutic window where knocking down the protein tips the balance away from aggregation and allows the cell’s own cleanup systems to regain control.
Other strategies under investigation include splice-switching therapeutics designed to restore normal STMN2 and UNC13A expression even in the absence of nuclear TDP-43, small molecules that inhibit the liquid-to-solid phase transition of TDP-43 droplets, and approaches that boost autophagy or proteasome activity to accelerate clearance of aggregates. None of these has yet reached late-stage clinical trials for ALS, but the convergence of multiple approaches on the same core biology is encouraging.
Biomarkers for Tracking TDP-43 Pathology
A major barrier to treating ALS is that by the time someone shows up with muscle weakness, substantial motor neuron loss has already occurred. Fluid biomarkers that can detect TDP-43 pathology earlier or track its progression are a high priority. Neurofilament light chain (NfL), a structural protein released from damaged axons, can be measured in cerebrospinal fluid and blood, and serves as both a diagnostic aid and a gauge of how quickly the disease is advancing.21PubMed Central. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS TDP-43 itself can be measured in cerebrospinal fluid, and combining TDP-43 and NfL measurements improves diagnostic accuracy over either marker alone. These biomarkers are also critical for clinical trials, where you need an objective measure of whether a treatment is slowing the underlying pathology rather than just masking symptoms.
Environmental Exposures That Raise TDP-43 Levels
While genetic mutations explain a minority of ALS cases, the majority are sporadic, arising without a clear inherited cause. Environmental factors that tip TDP-43 homeostasis may be part of the explanation. Dioxins and related environmental contaminants, acting through the aryl hydrocarbon receptor (AHR), can increase TDP-43 protein levels by up to threefold in human neuronal cell lines and in mouse brain. Chronic exposure leads to accumulation of both soluble and insoluble forms of TDP-43, primarily because the contaminants slow TDP-43 breakdown rather than speeding up its production.22Molecular Neurodegeneration. Dioxins and related environmental contaminants increase TDP-43 levels Blocking the AHR with antagonists or genetic knockdown prevented the TDP-43 increase, confirming that the effect runs through a specific receptor pathway rather than general toxicity. Whether real-world dioxin exposures at environmental levels are sufficient to meaningfully shift ALS risk in humans remains an open question, but the finding provides a concrete molecular link between a known class of pollutants and the protein at the center of ALS pathology.